Boston Scientific Corporation (BSX) Business Profile

What it does

Boston Scientific develops, manufactures and markets medical devices used by physicians and other medical professionals. Its products help diagnose and treat conditions affecting the heart and blood vessels, digestive and urinary systems, and nervous system, as well as some cancers. Many are designed for procedures that are less invasive than conventional surgery.

The company has two reporting segments. MedSurg includes devices used in endoscopy, urology and neuromodulation. These range from clips used to stop bleeding during digestive procedures to instruments for treating kidney stones and implants for managing chronic pain. Cardiovascular includes devices for treating heart rhythm disorders, preventing certain strokes, opening or treating diseased blood vessels and treating some cancers.

For example, the FARAPULSE system uses pulsed-field ablation to treat atrial fibrillation, a heart rhythm disorder. WATCHMAN devices close a small pouch in the heart in certain patients with atrial fibrillation who are at risk of stroke. Other products include pacemakers, drug-coated balloons, single-use scopes and spinal cord stimulators.

Boston Scientific sells to hospitals, clinics, outpatient facilities and medical offices, using its own sales teams and distributors. It was founded in 1979 and is headquartered in Marlborough. Michael F. Mahoney is chairman and chief executive officer.

How it makes money

Boston Scientific earns revenue by selling devices and related solutions for medical procedures. Its sales teams work with physicians and hospital administrators, while purchasing organizations and hospital networks also play a role in buying decisions. Pricing reflects competition over clinical outcomes, ease of use, reliability and efficiency, as well as pressure from buyers and reimbursement systems.

MedSurg brings together three businesses. Endoscopy sells devices used in digestive procedures, including stents, clips and single-use scopes. Urology supplies products for conditions such as kidney stones, enlarged prostates and incontinence. Neuromodulation sells devices for chronic pain and neurological movement disorders, including spinal cord and deep brain stimulation systems.

Cardiovascular covers a range of procedures. Its electrophysiology products include FARAPULSE and cardiac mapping systems; WATCHMAN devices address stroke risk in certain patients with atrial fibrillation. The segment also sells pacemakers and defibrillators, coronary and peripheral vascular devices, clot-removal technologies, and products used to treat cancer.

The portfolio includes both equipment and products used in individual procedures. Examples of repeat-use or replacement demand include single-use scopes and consumables used in radiofrequency ablation. The company also offers remote patient management and monitoring systems. It does not identify a company-wide recurring-revenue share in the available disclosures.

Gross profit was $13.854 billion in 2025; consolidated revenue was $5,138,000,000 in the third quarter of 2026. Sales growth in 2025 was driven in part by electrophysiology, including FARAPULSE, and by WATCHMAN and coronary therapies.

Customers and how it sells

Boston Scientific markets its products to hospitals, clinics, outpatient facilities and medical offices in 127 countries worldwide. Physicians and other medical professionals use the devices, while hospitals and other providers typically bill government programs or private insurers for the care delivered to patients.

Large group purchasing organizations, hospital networks and other buying groups represent a substantial portion of net sales. Each business has dedicated sales and marketing teams focused on specialist physicians and hospital service-line administrators. The company does not identify an individual customer’s share of revenue in the available disclosures.

Most net sales come from countries where Boston Scientific has its own direct sales organizations. It also uses distributors and dealers in certain countries and markets, including where maintaining a direct presence is not economical or strategic. Its international strategy includes expanding in emerging markets, which it defines as countries outside the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

In the third quarter of 2026, the United States was flat year over year on an operational basis, Europe, Middle East and Africa grew 6%, and Asia Pacific declined 1%. Boston Scientific cited the cyber incident and price pressure in China as factors affecting Asia Pacific.

Suppliers and costs

Boston Scientific manufactures medical devices using both widely available materials and custom-made components. Many components can be made from common raw materials or purchased from multiple sources, but some materials and components come from single sources because of quality, expertise, cost or regulatory considerations. The company does not name those suppliers.

The company monitors inventory, manufacturing, sterilization and distribution capacity and maintains recovery plans for potential disruptions. It says supply constraints can increase costs or prevent it from fully meeting demand. All of its medical device manufacturing facilities and key distribution sites are certified under the ISO 13485 quality system standard.

Manufacturing inputs, tariffs, distribution and wages affect costs. Selling expenses support product launches and higher sales, while research and development spending funds product development, clinical evidence and regulatory work. In 2025, higher sales of higher-margin products supported gross margin, partly offset by inventory charges from discontinuing the ACURATE platform, higher tariffs and other expenses.

The cyber incident also brought manufacturing and operating costs. Boston Scientific expects its restructuring program to produce over $500 million of savings over the next three years through measures including organizational changes, supply-chain optimization and back-office transformation.

Competitive position

Boston Scientific faces competition across its segments from large manufacturers with multiple product lines, smaller device companies focused on particular markets and lower-cost manufacturers. In China and certain other countries, domestic suppliers may benefit from their local status. Alternative therapies and technologies that could replace procedures using its devices also compete for patients and providers. The company does not identify a specific competitor by name in the available disclosures.

The company says its products compete on clinical and economic outcomes, ease of use, reliability, physician familiarity and price. Regulatory authorization, reimbursement approvals, quality systems and the ability to supply customers also affect its competitive success. Boston Scientific protects its technology through patents, trademarks, trade secrets and licenses; it says no single intellectual-property asset or license is material to the business as a whole.

Our reading: The breadth of its device portfolio, specialist sales teams and physician relationships provide a meaningful competitive foundation across several procedures, though their strength varies by market. Our reading: Intellectual property and regulatory requirements can help protect products, but neither eliminates competition from new devices or alternative treatments.

Boston Scientific says its electrophysiology market share has eroded as new pulsed-field ablation technologies have been adopted. It expects further erosion until FARAWAVE Ultra launches, now expected in early 2028. It also expects a new competitor in the WATCHMAN market in 2027.

Growth opportunities

Boston Scientific plans to invest in existing businesses, develop new technologies, expand internationally and enter adjacent markets. Its research and development work includes internal programs, clinical studies and technologies obtained through acquisitions and alliances. The company also works with research institutions, universities and clinicians to develop and test products.

FARAPULSE, WATCHMAN and coronary therapies contributed to Cardiovascular sales growth in 2025. Boston Scientific is developing later-generation products in both heart rhythm treatment and left atrial appendage closure. It expects to launch FARAWAVE Ultra in early 2028 and WATCHMAN Elite in 2029; enrollment in the WATCHMAN Elite clinical trial has begun. It also received clearances for several stone-management products and for a device used to treat severely calcified peripheral arteries.

Acquisitions are another route into new technologies. Boston Scientific acquired Nalu Medical in January 2026 for its chronic-pain portfolio. Its proposed acquisition of Penumbra would add products used to remove blood clots and blockages. The company now expects that transaction to close in early 2027, subject to remaining regulatory clearances.

Boston Scientific expects to enter several new markets over the next few years and estimates that they could unlock $25 billion in market opportunity by 2030. It also expects its current business pressures to make revenue and adjusted earnings per share growth challenging in 2027, excluding Penumbra. Those pressures include electrophysiology competition, WATCHMAN market conditions and China pricing.

Structural risks

• Competition and product timing: New technologies and lower-cost offerings can pressure sales and pricing. Boston Scientific has experienced electrophysiology share erosion and expects it to continue until its next product launch. Some major pipeline platforms have also experienced delays.

• Regulation and reimbursement: Devices need authorization in their markets, and regulators can require recalls or restrict production and distribution. Changes in coverage, payment or cost-containment policies may make providers less likely to select the company’s products.

• Supply and cyber disruption: Some components come from single sources, creating exposure to shortages or higher costs. A cyber incident disrupted operations in 2026; Boston Scientific estimated that it reduced third-quarter revenue by roughly $150 million. Operations were restored on September 8.

• Acquisitions and debt: Failure to integrate acquired businesses can hurt results. Boston Scientific has identified difficulty integrating Axonics, while the proposed Penumbra transaction remains subject to regulatory clearances. The company also identifies managing debt and maintaining credit ratings as financial risks.

• Pricing and trade: The company faces price pressure in China and expects additional China pricing headwinds in 2027. Tariffs, trade restrictions and supply-chain inflation can increase manufacturing and distribution costs.

Bottom line

Our reading

Our reading: Boston Scientific is a diversified device manufacturer whose business rests on physician adoption, clinical evidence and the ability to keep products available and approved. Its portfolio and international sales network span many procedures, but competition and referral changes are weighing on two important heart-device businesses. The next phase depends in part on product launches, acquisition execution and managing supply, pricing and regulatory pressures.